AstraZeneca PLC
AZN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $8,691,000 | $6,899,000 | $2,501,000 | -$265,000 |
| Dep. & Amort. | $5,065,000 | $4,934,000 | $5,480,000 | $6,530,000 |
| Deferred Tax | $0 | $0 | -$619,000 | -$615,000 |
| Stock-Based Comp. | $0 | $579,000 | $619,000 | $615,000 |
| Change in WC | -$893,000 | $300,000 | $3,757,000 | $2,021,000 |
| Other Non-Cash | -$1,002,000 | -$2,367,000 | -$1,930,000 | -$2,323,000 |
| Operating Cash Flow | $11,861,000 | $10,345,000 | $9,808,000 | $5,963,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,924,000 | -$1,361,000 | -$2,571,000 | -$2,200,000 |
| Net Acquisitions | -$3,927,000 | -$1,179,000 | -$1,061,000 | -$9,433,000 |
| Inv. Purchases | -$96,000 | -$136,000 | -$159,000 | -$184,000 |
| Inv. Sales/Matur. | $108,000 | $129,000 | $42,000 | $105,000 |
| Other Inv. Act. | -$2,141,000 | -$1,517,000 | $789,000 | $654,000 |
| Investing Cash Flow | -$7,980,000 | -$4,064,000 | -$2,960,000 | -$11,058,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $1,809,000 | -$965,000 | -$1,197,000 | $7,894,000 |
| Stock Issued | -$43,000 | $33,000 | $29,000 | $29,000 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | -$4,629,000 | -$4,481,000 | -$4,364,000 | -$3,856,000 |
| Other Fin. Act. | -$1,133,000 | -$1,154,000 | -$1,291,000 | -$418,000 |
| Financing Cash Flow | -$3,996,000 | -$6,567,000 | -$6,823,000 | $3,649,000 |
| Forex Effect | -$93,000 | -$60,000 | -$80,000 | -$62,000 |
| Net Chg. in Cash | -$208,000 | -$346,000 | -$55,000 | -$1,508,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $5,637,000 | $5,983,000 | $6,038,000 | $7,546,000 |
| End Cash | $5,429,000 | $5,637,000 | $5,983,000 | $6,038,000 |
| Free Cash Flow | $7,275,000 | $6,567,000 | $7,237,000 | $3,763,000 |